| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1cd8c26e69263bbbd1f8bd74a4019e50 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0647
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N65-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 |
| filingDate |
2009-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02d137e9e4d40de9ae35d178f17288c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55f4d492445d80ea7cdba6e85519e00e |
| publicationDate |
2010-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2743255-A1 |
| titleOfInvention |
Infarct area perfusion-improving compositions and methods of vascular injury repair |
| abstract |
The described invention provides pharmaceutical compositions for treating an infarct area injury and methods of treating or repairing the infarct area injury in a revascularized subject in the aftermath of an acute myocardial infarction resulting from a natural disease process by administering to the subject parenterally through a catheter a sterile pharmaceutical composition containing a therapeutically effective amount of a nonexpanded sterile isolated chemotactic hematopoietic stem cell product as a first therapeutic agent and optionally a therapeutically effective amount of at least one compatible second therapeutic agent. The infarct area-improving amount of the sterile isolated chemotactic hematopoietic stem cell product comprises an enriched population of isolated autologous CD34+ cells containing a subpopulation of potent cells expressing CXCR-4 and having CXCR-4-mediated chemotactic activity such that the enriched population of isolated autologous CD34+ hematopoietic stem cells provides at least 0.5 x 106 potent CD34+ cells expressing CXCR-4 and having CXCR-4 mediated chemotactic activity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11052118-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10111907-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10172888-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10851412-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3381456-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2785350-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10980838-B2 |
| priorityDate |
2008-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |